New Delhi, May 1 -- Diagnostics major Dr. Lal Path Labs saw revenue improve 17% year-on-year to Rs.703 crore in the March quarter (Q4FY26), beating consensus estimate by 5%. The jump was primarily led by higher sample volumes and better realizations.

Revenue grew 12.2% to Rs.2,763 crore in FY26. Sample volumes rose around 13% in Q4FY26 aided by demand rather than pricing tailwinds. Diagnostics is ultimately a scale business, so a sustainable volume growth is crucial rather than just price increases.

For FY27, management eyes early-to-mid-teens revenue growth driven by volumes and case mix rather than pricing. This growth will be supported by a fairly aggressive expansion plan of 12-15 new laboratories, one to two high-end radiology cent...